Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

First-quarter fiscal 2010 results announced by Senesco Technologies

First-quarter fiscal 2010 results announced by Senesco Technologies

Scientists solve 50-year-old thalidomide puzzle

Scientists solve 50-year-old thalidomide puzzle

Seattle Genetics commences phase I clinical trial of SGN-75 ADC for metastatic renal cell carcinoma

Seattle Genetics commences phase I clinical trial of SGN-75 ADC for metastatic renal cell carcinoma

Onyx Pharmaceuticals acquires Proteolix

Onyx Pharmaceuticals acquires Proteolix

Myeloma UK launches innovative clinical trial network

Myeloma UK launches innovative clinical trial network

EntreMed announces financial results for the third quarter of 2009

EntreMed announces financial results for the third quarter of 2009

PAF receives additional funding support for serving patients with multiple myeloma

PAF receives additional funding support for serving patients with multiple myeloma

Senesco's multiple myeloma drug candidate data to be presented at the AACR-NCI-EORTC conference

Senesco's multiple myeloma drug candidate data to be presented at the AACR-NCI-EORTC conference

Keryx Biopharmaceuticals to present KRX-0401 Phase 1/2 clinical trial data at the ASH meeting

Keryx Biopharmaceuticals to present KRX-0401 Phase 1/2 clinical trial data at the ASH meeting

Aeterna Zentaris reports consolidated revenues of $8.6 million for third quarter 2009

Aeterna Zentaris reports consolidated revenues of $8.6 million for third quarter 2009

Onyx Pharmaceuticals to present data on carfilzomib and ONX 0803 at the 51st ASH Annual Meeting

Onyx Pharmaceuticals to present data on carfilzomib and ONX 0803 at the 51st ASH Annual Meeting

Allos Therapeutics awards NCCN a grant to evaluate pralatrexate

Allos Therapeutics awards NCCN a grant to evaluate pralatrexate

Scientific article supports AEterna Zentaris' development of perifosine inhibitor

Scientific article supports AEterna Zentaris' development of perifosine inhibitor

Clinical Data announces financial results for its second fiscal quarter ended September 30, 2009

Clinical Data announces financial results for its second fiscal quarter ended September 30, 2009

TREANDA induces durable responses in indolent B-cell non-Hodgkin's lymphoma patients

TREANDA induces durable responses in indolent B-cell non-Hodgkin's lymphoma patients

Bortezomib lymphoma drug may be effective against bone cancer in children and teens: Study

Bortezomib lymphoma drug may be effective against bone cancer in children and teens: Study

EntreMed to present its Aurora A/angiogenic kinase inhibitor data at the AACR-NCI-EORTC conference

EntreMed to present its Aurora A/angiogenic kinase inhibitor data at the AACR-NCI-EORTC conference

NOXXON Pharma commences human dosing in Spiegelmer NOX-A12 clinical trial

NOXXON Pharma commences human dosing in Spiegelmer NOX-A12 clinical trial

Seminar on multiple myeloma

Seminar on multiple myeloma

NCI awards UAMS Myeloma Institute $19.5M grant

NCI awards UAMS Myeloma Institute $19.5M grant